PMC:7594251 / 2475-2646
Annnotations
LitCovid-PD-CLO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T14710 | 53-54 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T5958 | 74-81 | http://purl.obolibrary.org/obo/UBERON_0000473 | denotes | testing |
| T70818 | 127-128 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
LitCovid-PD-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T17 | 33-37 | Chemical | denotes | drug | http://purl.obolibrary.org/obo/CHEBI_23888 |
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 19 | 5-9 | Gene | denotes | high | Gene:104137 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T23 | 0-171 | Sentence | denotes | This high investment barrier for drug development is a result of numerous testing phases (Scheme 1), with each phase requiring a statistically significant number of cases. |